Association between the mood stabilizing treatment of bipolar disorder and risk of suicide attempts: A self-controlled case series study

Bipolar disorder (BPD) is associated with high rates of suicide attempts but the anti-suicidal effect of mood stabilizing agents remains unclear. This study aimed to examine the association between mood stabilizing agents (lithium, valproate, lamotrigine, carbamazepine or antipsychotics) and risk of suicide attempts in patients with BPD using self-controlled case series study design. Among 14,087 […]

Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on therapeutic strategies of the ILAE Commission on neuropsychobiology.

In 2008, the U.S. Food and Drug Administration (FDA) issued an alert to health care professionals about an increased risk of suicide ideation and suicide behavior in people treated with antiepileptic drugs (AEDs). Since then, a number of retrospective cohort and case-control studies have been published that are trying to address this issue, but gathered […]

An Update on Antiepileptic Drugs and Suicide: are There Definitive Answers yet?

Recently 4 publications examined suicidality & antiepileptic drug use among several databases & illustrated how biases affect the findings. None of the studies was able to control completely for the indication for which the antiepileptic drugs were prescribed or to account for the varying intensities with which different specialists monitored patients for suicidality. Though multiple […]

Assessing Suicidal Risk With Antiepileptic Drugs

The authors discuss the issue of suicide in epilepsy with special attention to antiepileptic drugs & the assessment of suicide in people with epilepsy. It has been suggested that early medical treatment with antiepileptic drugs might potentially reduce suicide risk in people with epilepsy, but it is of great importance that the choice of drugs […]

Antiepileptic Drugs and Suicidality

In this article, the association of epilepsy & antiepileptic drugs with psychiatric disease & suicidality are reviewed, perspective as to the significance & limitations of the American Food and Drug Administration’s findings are discussed, & some options for suicidality screening & their potential utility in clinical care are evaluated. (76 refs.) JA